BRCA2 and pancreatic neoplasm: In addition, these compounds exacerbated DNA damage and cell death in response to the PARP inhibitor olaparib in BRCA2-deficient Capan-1 cells and cooperated with gemcitabine to the killing of pancreatic cancer cells.